| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.21 | 0.0002 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0003 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0003 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0004 |